

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (original): A method for treatment of neuropsychiatric disorders which comprises administration of a D-serine transport inhibitor at a dose sufficient to enhance NMDA receptor-mediated neurotransmission in vivo.
2. (original): The method of claim 1 wherein the disorder is associated with decreased *N*-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission.
3. (original): The method of claim 1 wherein the disorder is a psychotic disorder.
4. (original): The method of claim 3 wherein the psychotic disorder is schizophrenia.
5. (original): The method of claim 1 wherein the disorder is Alzheimer's disease, bipolar illness, depression and anxiety disorders, stroke or epilepsy.
6. (original): The method of claim 1 wherein the disorder is age associated memory impairment, closed head injury or attention deficit disorder.
7. (original): The method of claim 1 wherein such agent is administered orally.
8. (original): The method of claim 1 wherein a D-serine transport inhibitor is administered parenterally.
9. (original): A method for augmentation of *N*-methyl-D-aspartate receptor-mediated neurotransmission in vivo which comprises administration of a D-serine transport antagonist.

10. (original): The method of claim 1 or 9 wherein the antagonist is an inhibitor of D-serine transport mediated through system ASC.

11. (original): The method of claim 1 or 9 wherein the antagonist is an inhibitor of systems L, N, A or Gly.

12. (original): The method of claim 1 or 9 wherein the antagonist is an inhibitor of alanine-sensitive D-serine transport.

13. (original): The method of claim 1 or 9 where the antagonist is an inhibitor of alanine-insensitive D-serine transport.

14. (original): The method of claim 1 or 9 wherein the agent is glycyldodecylamide, D-serine dodecylamide or D-alanine dodecylamide.

15. (original): The method of claim 1 or 9 wherein the agent is used in combination with typical or atypical antipsychotics administered orally, parenterally or by depot formulation.

16. (original): The method of claim 1 or 9 wherein the agent is used in combination with other treatments commonly used in schizophrenia, including but not limited to antidepressants, mood stabilizers, or antianxiety agents.

17. (original): The method of claim 1 or 9 wherein the agent is used in combination with a glycine transport inhibitor.

18. (currently amended): A composition for treating schizophrenia ~~incorporating~~ comprising an effective amount of a D-serine transport inhibitor.

19. (original): A composition of claim 18, wherein the inhibitor is glycyldodecylamide, D-serine dodecylamide or D-alanine dodecylamide.

20. (original): A composition of claim 18 wherein the inhibitor is a derivative of serine or alanine having effectiveness in inhibiting D-serine transport in vivo.

21. (currently amended): A composition of claim 18 wherein the D-serine transport inhibitor is present in an amount sufficient to augment NMDA-mediated neurotransmission and is combined with a typical or atypical antipsychotic agent administerable orally or parenterally.

22. (original): A composition of claim 20 wherein the derivative is a hydrophobic derivative of serine or alanine.

23. (original): A composition of claim 22 wherein the derivative is serine or alanine having a hydrophobic group linked to at least one of the C- and N-terminus.

24. (currently amended): A composition of claim 22 where the hydrophobic group is selected from the group consisting of alkyl(C1-C13), unsubstituted or substituted phenyl, phenylalkyl (C1-C13), cyano, halogen and ~~or~~ haloalkyl (C1-C13).

25. (original): A method of claim 1 wherein a composition of claim 20 is used.

26. (original): A method of claim 9 wherein a composition of claim 20 is used.